Schizophrenia Research
Volume 93, Issue 1 , Pages 99-108 , July 2007

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial

  • Trino Baptista

      Affiliations

    • Department of Physiology, Los Andes University Medical School, PO Box 93, Mérida, 5101-A, Venezuela
    • Corresponding Author InformationCorresponding author. Tel.: +58 416 676 0320.
    • ,
  • Nairy Rangel

      Affiliations

    • Psychiatric Institute “Dr. Raúl Castillo”, Peribeca, San Cristóbal, Táchira State, Venezuela
    • ,
  • Virginia Fernández

      Affiliations

    • Institute of Clinical Research “Dr. Américo Negrette”, Zulia University Medical School, Maracaibo, Venezuela
    • ,
  • Edgardo Carrizo

      Affiliations

    • Institute of Clinical Research “Dr. Américo Negrette”, Zulia University Medical School, Maracaibo, Venezuela
    • ,
  • Yamily El Fakih

      Affiliations

    • Department of Psychiatry, Los Andes University Medical School, Mérida, Venezuela
    • ,
  • Euderruh Uzcátegui

      Affiliations

    • Department of Psychiatry, Los Andes University Medical School, Mérida, Venezuela
    • ,
  • Tatiana Galeazzi

      Affiliations

    • LABIMET, Los Andes University Medical School, San Cristóbal, Venezuela
    • ,
  • María A. Gutiérrez

      Affiliations

    • CATESFAM, Maracaibo, Venezuela
    • ,
  • Mercedes Servigna

      Affiliations

    • CATESFAM, Maracaibo, Venezuela
    • ,
  • Adriana Dávila

      Affiliations

    • Psychiatric Institute “Dr. Raúl Castillo”, Peribeca, San Cristóbal, Táchira State, Venezuela
    • ,
  • Marycelvia Uzcátegui

      Affiliations

    • Department of Psychiatry, Los Andes University Medical School, Mérida, Venezuela
    • ,
  • Ana Serrano

      Affiliations

    • Department of Psychiatry, Los Andes University Medical School, Mérida, Venezuela
    • ,
  • Lisette Connell

      Affiliations

    • Institute of Clinical Research “Dr. Américo Negrette”, Zulia University Medical School, Maracaibo, Venezuela
    • ,
  • Serge Beaulieu

      Affiliations

    • Douglas Hospital Research Center, McGill University, Montreal, QC, Canada
    • ,
  • Enma Araujo de Baptista

      Affiliations

    • Pharmacy School, Department of Microbiology, Los Andes University Medical School, Mérida, Venezuela

Received 11 February 2007 ,Revised 20 March 2007 ,Accepted 21 March 2007.

References 

  1. Assuncao SS, Ruschel SI, Rosa L, de C, Campos JA, Alves MJ, et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev. Bras. Psiquiatr. 2006;28(4):270–276
  2. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?. Can. J. Psychiatry. 2002;47(8):742–749
  3. Baptista T, Alvarez L, Cubillán E, Mendoza S, Hernandez L. Metformin in the obesity associated to antipsychotic drug-administration: a pilot study. J. Clin. Psychiatry. 2001;62(8):653–655
  4. Baptista T, Ying Kin NMK, Beaulieu S. Treatment of the metabolic disturbances caused by antipsychotic drugs. Clin. Pharmacokinet. 2004;43(1):1–15
  5. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can. J. Psychiatry. 2006;51(3):192–196
  6. Baptista T, Sandia I, LaCruz A, Rangel N, de Mendoza S, Beaulieu S, et al. Insulin counter-regulatory factors, fibrinogen and c-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int. Clin. Psychopharmacol. 2007;22(2):69–76
  7. Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 2004;89(8):3943–3948
  8. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur. Neuropsychopharmacol. 2003;13(2):81–85
  9. Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, et al. Weight loss in overweight patients maintained on atypical antipsychotic agents. Int. J. Obes. (Lond). 2006;30(6):1011–1016
  10. Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 2006;61(10):1075–1081
  11. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. Clin. Psychol. 2002;22(3):244–251
  12. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst. Rev. 2007;24(1):CD005148
  13. Festa A, D'Agostino R, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler. Thromb. Vasc. Biol. 1999;19(3):562–568
  14. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42–47
  15. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 1996;19(9):920–926
  16. Glueck CJ, Aregawi D, Agloria M, Winiarska M, Sieve L, Wang P. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism. 2006;55(12):1582–1589
  17. Glueck CJ, Golnik KC, Aregawi D, Goldenberg N, Sieve L, Wang P. Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. Transl. Res. 2006;148(5):215–222
  18. Glueck CJ, Aregawi D, Winiarska M, Agloria M, Luo G, Sieve L, et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. 2006;19(6):831–842
  19. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al. Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54(5):1566–1572
  20. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. Cent. Nerv. Syst. Drugs. 2002;16(11):765–766
  21. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J. Clin. Endocrinol. Metab. 2005;90(8):4593–4598
  22. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am. J. Psychiatry. 2005;162(5):954–962
  23. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50(12):1457–1461
  24. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J. Clin. Psychopharmacol. 2005;25(3):255–258
  25. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin in treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am. J. Psychiatry. 2006;163(12):2072–2079
  26. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353(12):1209–1223
  27. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome-a randomised, double-blind, placebo-controlled trial. BJOG. 2006;113(7):817–824
  28. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J. Clin. Psychiatry. 2004;65(4):471–477
  29. Mogul HR, Peterson SJ, Weinstein BI, Zhang S, Southren AL. Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia. Heart Dis. 2001;3(5):285–292
  30. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am. J. Psychiatry. 2002;159(4):655–657
  31. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry. 1997;58(Suppl 10):45–49
  32. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can. J. Psychiatry. 2006;51(8):480–491
  33. Pedersen J. The effect of metformin on weight loss in obesity. Acta Endocrinol. (Copenh). 1965;49(7):479–486
  34. Pedersen J, Olesen ES. Observations on the mechanism of increased weight loss during metformin administration in obesity. Acta Endocrinol. (Copenh). 1968;57(4):683–688
  35. Seufert J, Lubben G, Dietrich K, Bates PC. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin. Ther. 2004;26(6):805–818
  36. Spitzer RL, Williams JBW, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch. Gen. Psychiatry. 1992;49(8):624–629
  37. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod. 2006;21(1):80–89
  38. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58(suppl 1):31–39

PII: S0920-9964(07)00153-3

doi: 10.1016/j.schres.2007.03.029

Schizophrenia Research
Volume 93, Issue 1 , Pages 99-108 , July 2007

Article Tools